FTO and Alzheimer disease: Given that disrupted m6A signaling is believed to play a role in AD pathogenesis, MO-I-500, a newly developed pharmacological inhibitor of FTO, has been revealed to promote cell survival and inhibit mitochondrial dysfunction in streptozotocin-treated astrocytes [261].